Despite hitting the market more than a year ago with steep discounts, biosimilars for AbbVie’s blockbuster arthritis treatment Humira (adalimumab) have managed to take only 4% of the market share away from the branded reference product, according to the latest quarterly report from Samsung Bioepis.
Tag Archive for: Amjevita
Boehringer Ingelheim on Monday unveiled lower wholesale pricing for its adalimumab-adbm injection, the company’s interchangeable biosimilar to AbbVie’s blockbuster chronic inflammatory therapy Humira (adalimumab).
Consumer healthcare brand CVS Health on Wednesday launched Cordavis, a wholly owned subsidiary focused on the growing U.S. biosimilars market that will work directly with manufacturers.
AbbVie Inc. on Thursday missed quarterly revenue estimates for its newer treatments, fueling concerns over the drugmaker’s attempts to cushion the blow to sales from blockbuster Humira losing patent exclusivity.
AbbVie’s weak forecast suggests that Humira rivals could nibble away at the blockbuster drug’s market share at a faster pace this year than analysts’ projections.
U.S. patients will finally get access to cheaper versions of AbbVie Inc.’s blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
